viewSareum Holdings PLC

Sareum surges as it signals progress on pre-clinical programmes

"The potential for our two preclinical TYK2/JAK1 inhibitors in autoimmune diseases and cancer is gaining increasing clinical validation and we are convinced that SDC-1801 and SDC-1802 represent strong and well-differentiated candidates to address diseases within these areas," said Dr Tim Mitchell, the Sareum CEO.

Drug development
"We are focused on advancing these exciting preclinical candidates towards human trials as quickly as possible, aiming for first-in-man studies to begin in 2020."

Sareum Holdings PLC (LON:SAR), the specialist small molecule drug development business, has hailed the recent progress of its clinical and pre-clinical programmes.

Following last week’s announcement of preliminary efficacy data for SRA737, a cancer drug it helped to develop, the company provided the market with an update on other developments within its active pre-clinical portfolio.

READ Sareum Holdings hails early-stage efficacy data for cancer drug

Sareum's SDC-1801 and SDC-1802 drug candidates, which are respectively being developed to treat autoimmune diseases and cancers are progressing through pre-clinical development and should undergo first in-human clinical trials in 2020.

Both Sareum programmes have progressed well since being chosen in September 2018 for further development.

Data items arising from some of the development work are being prepared for submission to a peer-reviewed publication and a conference presentation, Sareum said.

Sareum's recent activities have focused on toxicology studies designed to gain insight into the maximum-tolerated doses of SDC-1801 and SDC-1802 in rodents.

SDC-1801, the autoimmune diseases candidate, is further advanced and currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies; a maximum tolerated dose has yet to be reached.

In addition, the company has been exploring reliable manufacturing routes to produce each candidate for preclinical and clinical studies; such a route has been developed for SDC-1801 and activities continue to confirm a route of synthesis for SDC-1802.

"We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes,” said Dr Tim Mitchell, the chief executive officer of Sareum.

Shares in Sareum were up 4.8% in early deals.


Quick facts: Sareum Holdings PLC

Price: 0.885 GBX

Market: AIM
Market Cap: £28.81 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...



Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

2 days, 12 hours ago

2 min read